Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK Early Access Granted For Argenx’s Generalized Myasthenia Gravis Treatment

Efgartigimod Is Being Investigated For Several High-Need Autoimmune Conditions

Executive Summary

Patients in the UK with generalized myasthenia gravis are being allowed to receive argenx’s yet-to-be approved drug efgartigimod.

You may also be interested in...



Argenx Eyes Hat-Trick Of Successful Launches For Vyvgart After CHMP Thumbs-Up

Anant Murthy, general manager of Argenx Europe, tells Scrip that the commercial infrastructure is in place for Vyvgart to enjoy a strong launch for the rare neuromuscular disorder which will mirror those seen in the US and Japan.

Argenx Enters Japan With Smooth Approval – How Was It Possible?

Belgian bioventure Argenx has made an unusually smooth commercial entry to Japan with Vyvgart almost as fast as the launch of the myasthenia gravis drug in the US. Its founder admits it was a “bold move” for a European pharma company and revealed how the unexpected entrance was made possible.

Analysts Admire Argenx's Vyvgart Launch

The generalized myasthenia gravis-approved drug passed the $20m mark in sales for the first quarter, comfortably surpassing analyst estimates.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS146256

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel